Skip to main content

Table 2 Results of multivariate regression analysis

From: How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

Dependent variable: Δ central systolic blood pressure

Dependent variable: Δ central pulse pressure

Model 1

Beta

p-value

Model 2

Beta

p-value

Model 1

Beta

p-value

Model 2

Beta

p-value

Sex

0.134

0.379

Sex

0.195

0.191

Sex

0.155

0.255

Sex

0.211

0.110

Age

− 0.159

0.286

Age

− 0.186

0.205

Age

− 0.259

0.054

Age

− 0.282

0.032

Δ HbA1c

− 0.022

0.892

Δ Fasting plasma glucose

− 0.043

0.788

Δ HbA1c

0.012

0.933

Δ Fasting plasma glucose

− 0.169

0.238

Δ Copeptin

0.057

0.701

Δ Copeptin

0.054

0.710

Δ Copeptin

0.031

0.813

Δ Copeptin

0.037

0.769

Δ Hematocrit

− 0.092

0.565

Δ Hematocrit

− 0.096

0.556

Δ Hematocrit

− 0.145

0.309

Δ Hematocrit

− 0.189

0.192

Δ Heart rate

0.001

0.997

Δ Heart rate

0.043

0.787

Δ Heart rate

− 0.123

0.392

Δ Heart rate

− 0.056

0.686

Δ LDL-cholesterol

0.095

0.615

Δ LDL-cholesterol

0.074

0.631

Δ LDL-cholesterol

− 0.126

0.365

Δ LDL-cholesterol

− 0.146

0.287

Δ Uric acid

− 0.083

0.642

Δ Uric acid

− 0.027

0.878

Δ Uric acid

− 0.124

0.438

Δ Uric acid

− 0.112

0.478

Δ Systolic BP

0.412

0.018

Δ Systolic BP

0.355

0.024

Δ Systolic BP

0.364

0.019

Δ Systolic BP

0.332

0.017

Δ hsCRP

0.171

0.278

Δ hsCRP

0.192

0.231

Δ hsCRP

0.305

0.033

Δ hsCRP

0.347

0.017

  1. Model 1: Multivariate regression analysis was performed including the parameters sex, age and change of the following parameters under treatment with empagliflozin: HbA1c (model 1), copeptin concentration, hematocrit, 24-h ambulatory heart rate, LDL-cholesterol, uric acid, systolic 24-h ambulatory blood pressure and hsCRP. Model 2 included besides the other previously mentioned parameters fasting plasma glucose instead of HbA1c. LDL-cholesterol low density lipid cholesterol, hsCRP high sensitive C-reactive protein, heart rate 24-h ambulatory heart rate, systolic BP systolic 24-h ambulatory blood pressure, “Δ” refers to the changes due to empagliflozin treatment corrected for the placebo changes
  2. Italic values indicate significance of p-value (p < 0.05)